SPY458.97-10.47 -2.23%
DIA349.02-9.01 -2.52%
IXIC15,491.66-353.57 -2.23%

HC Wainwright & Co. Maintains Buy on aTyr Pharma, Lowers Price Target to $11

HC Wainwright & Co. analyst Joseph Pantginis maintains aTyr Pharma (NASDAQ:LIFE) with a Buy and lowers the price target from $18 to $11.

Benzinga · 11/11/2021 06:13
HC Wainwright & Co. analyst Joseph Pantginis maintains aTyr Pharma (NASDAQ:LIFE) with a Buy and lowers the price target from $18 to $11.